James Crowe
Faculty Member
Last active: 3/31/2019

  1. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE (2014) Virology : 139-44
    › Primary publication · 24725940 (PubMed) · PMC4004766 (PubMed Central)
  2. Differential accessibility of a rotavirus VP6 epitope in trimers comprising type I, II, or III channels as revealed by binding of a human rotavirus VP6-specific antibody. Aiyegbo MS, Eli IM, Spiller BW, Williams DR, Kim R, Lee DE, Liu T, Li S, Stewart PL, Crowe JE (2014) J Virol 88(1): 469-76
    › Primary publication · 24155406 (PubMed) · PMC3911710 (PubMed Central)
  3. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM (2014) PLoS Pathog 10(10): e1004386
    › Primary publication · 25275316 (PubMed) · PMC4183589 (PubMed Central)
  4. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS (2014) Proc Natl Acad Sci U S A 111(5): 1939-44
    › Primary publication · 24385585 (PubMed) · PMC3918811 (PubMed Central)
  5. Committing the Oldest Sins in the Newest Kind of Ways-Antibodies Targeting the Influenza Virus Type A Hemagglutinin Globular Head. Krause JC, Crowe JE (2014) Microbiol Spectr 2(5)
    › Primary publication · 26104373 (PubMed)
  6. Combining single RNA sensitive probes with subdiffraction-limited and live-cell imaging enables the characterization of virus dynamics in cells. Alonas E, Lifland AW, Gudheti M, Vanover D, Jung J, Zurla C, Kirschman J, Fiore VF, Douglas A, Barker TH, Yi H, Wright ER, Crowe JE, Santangelo PJ (2014) ACS Nano 8(1): 302-15
    › Primary publication · 24351207 (PubMed) · PMC3906890 (PubMed Central)
  7. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE, Lok SM (2014) EMBO Mol Med 6(3): 358-71
    › Primary publication · 24421336 (PubMed) · PMC3958310 (PubMed Central)
  8. Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. Almagro JC, Gilliland GL, Breden F, Scott JK, Sok D, Pauthner M, Reichert JM, Helguera G, Andrabi R, Mabry R, Bléry M, Voss JE, Laurén J, Abuqayyas L, Barghorn S, Ben-Jacob E, Crowe JE, Huston JS, Johnston SA, Krauland E, Lund-Johansen F, Marasco WA, Parren PW, Xu KY (2014) MAbs 6(3): 577-618
    › Primary publication · 24589717 (PubMed) · PMC4011904 (PubMed Central)
  9. Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. Benhnia MR, Maybeno M, Blum D, Aguilar-Sino R, Matho M, Meng X, Head S, Felgner PL, Zajonc DM, Koriazova L, Kato S, Burton DR, Xiang Y, Crowe JE, Peters B, Crotty S (2013) J Virol 87(3): 1569-85
    › Primary publication · 23152530 (PubMed) · PMC3554146 (PubMed Central)
  10. Universal flu vaccines: primum non nocere. Crowe JE (2013) Sci Transl Med 5(200): 200fs34
    › Primary publication · 23986396 (PubMed)